Key facts
- Praeventix’s last known valuation is $25.0M (Feb 2026).
- It has raised $14.1M across 3 recorded rounds; the latest was Seed Round ($3.0M) in Feb 2026.
- Notable investors include Tellus BioVentures.
- Praeventix has filed 5 Form Ds with the SEC since 2022, most recently Feb 2026 ($3.0M sold to 3 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Praeventix
Funding rounds
3 roundsAbout Praeventix
Developer of novel serotonergic therapeutics and signal transduction-modulating agents designed for the treatment of inflammatory disorders and chronic medical conditions. The company focuses on the development of potent and selective receptor antagonists to address unmet clinical needs in chronic pruritus, inflammatory bowel disease, and cocaine use disorder, enabling medical researchers and healthcare providers to deliver targeted treatment options that improve patient quality of life through the mitigation of debilitating physiological symptoms.
- Sector
- Healthcare
- HQ
- Exton, PA, United States
- Founded
- 2015
- Website
- praeventix.com/
- Ownership
- Privately Held (backing)
Praeventix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Praeventix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Praeventix in its N-PORT filings yet. We sweep new filings monthly.